Biotech entity

BioLife Solutions

Company BLFS

All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Indivior, the most common co-covered peer. We currently track 1 Biotech story that mention BioLife Solutions, all published on February 27, 2026.

Last mentioned: Feb 27, 2026

Entity pulse

Recent coverage · BioLife Solutions

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about BioLife Solutions

All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Indivior, the most common co-covered peer. We currently track 1 Biotech story that mention BioLife Solutions, all published on February 27, 2026. Each carries 19 original sources on average.

Stories tracked
1
Sources per story
19

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering BioLife Solutions. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning BioLife Solutions 1

Pharma Positive

Pharma and Biotech Sector Signals Strategic Pivot Toward Profitable Scaling

The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.

19 sources

BioLife Solutions is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.